# Gewu Zhihe Biotechnology (Beijing) Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gewu-zhihe-biotechnology-beijing-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.iomicsbio.com
- Total disclosed funding: $15M
- Latest round: Series A (Jun 20, 2022)
- Investors on record: 3

## About

Established in 2019 and based in Beijing, China, Gewu Zhihe Biotechnology (Beijing) Co., Ltd is a medical health company that focuses on developing brain disease tests and products. The company's chairman and founder, John Xu, has more than 20 years of experience in research and clinical diagnostics, and has led his team to obtain more than 30 Class II and III IVD certificates; he has been granted 50 domestic and foreign patents (25 US patents); and has published more than 10 high-level SCI academic papers. In April 2023, it raised strategic investment from new investors.

The company is developing a digital ELISA platform that includes a digital ELISA microfluidic chip, assay instrument and supporting software, as well as related assay kits. In addition, this platform features technologies related to microfluidics, automation, microscopic imaging, computational graphics, surface chemistry, antibody development and protein labeling assays.

The company plans to use the series A funding for continued development of a series of independent innovative technology platforms in the direction of proteomics and spatialomics, and accelerated the development and registration filing of a new generation of independently developed ultrasensitive single-molecule protein detection system and related neurodegenerative disease marker detection kits.

## Funding rounds

- Series A, Jun 20, 2022, $15M — Oriza Holdings, Apricot Capital
- Angel, Dec 22, 2020 — 3E Bioventures Capital

## Investors

- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Angel
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series A